For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

LL-37: origin, structure and research history

Research Library › Peptide Fragments

LL-37 is a naturally occurring 37-amino-acid antimicrobial peptide and the only cathelicidin encoded in the human genome; it is cleaved from a larger precursor protein, hCAP18. It was first reported in 1995 as FALL-39 by B. Agerberth, G.H. Gudmundsson, H.G. Boman and colleagues, and the mature LL-37 form was described in 1996. As of 22 Oct 2026 no approval of LL-37 by any regulator has been found, and it is not FDA-approved.

Key facts

TypeNatural 37-amino-acid antimicrobial peptide (human cathelicidin)
Derived fromPrecursor protein hCAP18, produced by white blood cells
Other namesCathelicidin LL-37, FALL-39 (predicted precursor peptide), ropocamptide (drug candidate)
First described1995 as FALL-39; mature LL-37 described 1996
Discovered byB. Agerberth, G.H. Gudmundsson, H.G. Boman and colleagues; gene also cloned independently by J.W. Larrick's team
Natural rolePart of innate host defense against bacteria
Regulatory status (Oct 2026)Not FDA-approved; removed from FDA Category 2 in April 2026 pending advisory review planned before end of February 2027

Who discovered it

LL-37 was first reported in 1995 by B. Agerberth and G.H. Gudmundsson, working with H.G. Boman and colleagues [1]. A team led by J.W. Larrick independently cloned the same gene, with results reported in 1996 [2]. Also in 1996, Gudmundsson, Agerberth and co-workers described how the precursor is processed into the mature peptide in white blood cells [3].

The Swedish company Promore Pharma later developed a drug candidate based on LL-37, named ropocamptide [4].

Structure and natural role

LL-37 is cut from a larger protein called hCAP18, which is produced by granulocytes, a class of white blood cells. The peptide was first predicted from the gene as a 39-amino-acid sequence, FALL-39. The mature peptide turned out to be 37 amino acids long and to begin with two leucines, which gives LL-37 its name [1, 3].

It belongs to the cathelicidin family of antimicrobial peptides, part of the innate immune system’s defense against bacteria. Laboratory studies have also reported interactions with skin cells and fibroblasts [3, 4].

Why it was studied

The original search was for a human counterpart to PR-39, an antibacterial peptide found in pig intestine. At the time, defensins were the only known human peptide antibiotics [1]. The 1996 gene study concluded that FALL39 is the only member of the cathelin gene family in the human genome [3].

Promore Pharma investigated ropocamptide as a topical gel in a research program on venous leg ulcers. Its phase IIb trial, HEAL LL-37, enrolled 144 patients in Sweden and Poland; the company reported no statistically significant difference among the three study groups in the overall analysis [4, 5]. Promore later merged into PMD Device Solutions at the end of 2023, and bankruptcy notices followed in December 2024 and January 2025 [6, 7].

Research timeline

  • 1995: FALL-39 reported, expressed in bone marrow and testis [1]
  • 1996: Processing to mature LL-37 in granulocytes described [3]
  • 2020: Promore reports phase IIb HEAL LL-37 results [4]
  • 2023: Promore merges into PMD Device Solutions [6]
  • April 2026: FDA removes LL-37 from its Category 2 compounding list [8]

Regulatory status as of October 2026

No regulatory approval of LL-37 or ropocamptide has been found in any country, and it is not FDA-approved. The FDA’s list of bulk substances that may present significant safety risks in compounding cited animal findings related to male reproduction and possible tumor-promoting effects [9].

In April 2026 the FDA removed LL-37 from that Category 2 list, pending a review by its Pharmacy Compounding Advisory Committee planned before the end of February 2027 [8]. On 14 Oct 2026 an FDA interim access policy covering certain peptides was sent to the White House for review; its contents were not public [10].

LL-37 is not named on the 2026 WADA Prohibited List; section S0 covers substances with no approval for human therapeutic use [11].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

What is LL-37?

LL-37 is a 37-amino-acid antimicrobial peptide, the only cathelicidin made by humans, cleaved from the precursor protein hCAP18 [1, 3].

Who discovered LL-37?

B. Agerberth, G.H. Gudmundsson, H.G. Boman and colleagues first reported it as FALL-39 in 1995, and described the mature LL-37 form in 1996 [1, 3].

Why is it called LL-37?

The mature peptide is 37 amino acids long and begins with two leucine (L) residues [3].

Is LL-37 FDA approved?

No. As of 22 Oct 2026 LL-37 is not FDA-approved, and an FDA advisory review of its compounding status is planned before the end of February 2027 [8].

Sources

  1. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA. 1995;92(1):195–199. PMID 7529412. Link
  2. INSERM DSIMB RESPIRE database. Cathelicidin antimicrobial peptide (CAMP): discovery and naming. Link
  3. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem. 1996;238(2):325–332. PMID 8681941. Link
  4. Promore Pharma AB. Press release on the phase IIb HEAL LL-37 study of ropocamptide. 19 Nov 2020. Link
  5. Promore Pharma AB. Interim report January–September 2020. Link
  6. BioSpace. PMD Device Solutions: new name and ticker symbol (formerly Promore Pharma), Jan 2024. Link
  7. MFN. Promore Pharma / PMD Device Solutions press releases, incl. bankruptcy notices 22 Dec 2024 and 14 Jan 2025. Link
  8. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
  9. U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (KPV and cathelicidin LL-37 entries). Content current as of 22 Apr 2026. Link
  10. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
  11. World Anti-Doping Agency. 2026 Prohibited List. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top